Kura Oncology Announces FDA Clearance Of IND Application For Ziftomenib To Treat Advanced GIST; Preclinical Data Suggest Combination With Imatinib Could Resensitize Patients And Induce Durable Responses; Phase 1 Study To Begin In 1H 2025
Portfolio Pulse from Benzinga Newsdesk
Kura Oncology has received FDA clearance for its IND application for Ziftomenib to treat advanced GIST. Preclinical data suggest that combining Ziftomenib with Imatinib could resensitize patients and induce durable responses. A Phase 1 study is set to begin in the first half of 2025.
August 08, 2024 | 11:38 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kura Oncology has received FDA clearance for its IND application for Ziftomenib to treat advanced GIST. Preclinical data suggest that combining Ziftomenib with Imatinib could resensitize patients and induce durable responses. A Phase 1 study is set to begin in the first half of 2025.
FDA clearance for the IND application is a significant milestone for Kura Oncology, indicating regulatory approval to proceed with clinical trials. The promising preclinical data and the upcoming Phase 1 study could positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100